ArticleCancer immunology, immunotherapy : CII2020

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.

Mikiya Ishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.